Aczone dapsone topical gel regulatory update

FDA approved an NDA for Aczone 5% dapsone topical gel to treat acne vulgaris. QLT will conduct a 6-month Phase IV trial in 50 acne patients with glucose 6-phosphate dehydrogenase (G6PD) enzyme deficie...